



CITY OF DOVER, DELAWARE
MAYOR'S BLUE RIBBON OPIOID USE DISORDER
(OUD)

TASKFORCE COMMITTEE MEETING

May 5, 2026, at 5:45 PM [Tuesday]

City Hall Council Chambers, 15 Loockerman Plaza, Dover, Delaware

AGENDA

INVOCATION – Mrs. Toni Jordan

PLEDGE OF ALLEGIANCE – Honorable Eric L. Buckson

AGENDA ADDITIONS/DELETIONS

AGENDA ITEMS:

- 1. Mr. Brad Owens** - Executive Director of the Delaware Prescription Opioid Settlement Distribution Commission (**POSDC**).
Application Process
 - a.** Public Interest Form:
 - b.** Notification & Portal:
 - c.** Review:
- 2. Discussion concerning Youth-Focused Campaigns:** Allocate funding for targeted “**Real Cost Media Campaigns and Programs**” aimed at preventing opioid use among youth and other vulnerable demographics. Special attention should be given to the unique needs of communities disproportionately affected by the epidemic, including homeless populations and communities of color, to ensure effective engagement and support.
- 3. Discussion regarding partnership with the Delaware Division of Public Health (DPH) Mobil Community Health Service, the Mayor’s Blue Ribbon OUD Taskforce (OUD) and Dover Human Relations Commission (DHRC) for Quality of Life and Community Well-being Achievements.**
 - This approach prioritizes immediate access to resources over enforcement which aligns with the goals of the Dover Opioid Use Disorder (**OUD**) Taskforce, which aims to address the high number of individuals panhandling at intersections like **Route 8** and **Route 13** through compassionate intervention rather than criminalization.

THE AGENDA ITEMS AS LISTED MAY NOT BE CONSIDERED IN SEQUENCE. PURSUANT TO 29 DEL. C. §10004(e)(2), THIS AGENDA IS SUBJECT TO CHANGE TO INCLUDE THE ADDITION OR THE DELETION OF ITEMS, INCLUDING EXECUTIVE SESSIONS, WHICH ARISE AT THE TIME OF THE MEETING



CITY OF DOVER, DELAWARE

EXHIBIT E List of Opioid Remediation Uses Schedule A Core Strategies
Schedule A

<file:///C:/Users/Roysu/OneDrive/Documents/Exhibit-E-Final-Distributor-Settlement-Agreement-8-11-21.pdf>

- A. NALOXONE OR OTHER FDA-APPROVED DRUG TO REVERSE OPIOID OVERDOSES
 - B. MEDICATION-ASSISTED TREATMENT (“MAT”) DISTRIBUTION AND OTHER OPIOID-RELATED TREATMENT
 - C. PREGNANT & POSTPARTUM WOMEN
 - D. EXPANDING TREATMENT FOR NEONATAL ABSTINENCE SYNDROME (“NAS”)
 - E. EXPANSION OF WARM HAND-OFF PROGRAMS AND RECOVERY SERVICES
 - F. TREATMENT FOR INCARCERATED POPULATION
 - G. PREVENTION PROGRAMS
 - H. EXPANDING SYRINGE SERVICE PROGRAMS
-

Schedule B

PART ONE: TREATMENT

- A. TREAT OPIOID USE DISORDER (OUD)
- B. SUPPORT PEOPLE IN TREATMENT AND RECOVERY
- C. CONNECT PEOPLE WHO NEED HELP TO THE HELP THEY NEED (CONNECTIONS TO CARE)
- D. ADDRESS THE NEEDS OF CRIMINAL JUSTICE-INVOLVED PERSONS
- E. ADDRESS THE NEEDS OF PREGNANT OR PARENTING WOMEN AND THEIR FAMILIES, INCLUDING BABIES WITH NEONATAL ABSTINENCE SYNDROME

PART TWO: PREVENTION

- F. PREVENT OVER-PRESCRIBING AND ENSURE APPROPRIATE PRESCRIBING AND DISPENSING OF OPIOIDS
- G. PREVENT MISUSE OF OPIOIDS
- H. PREVENT OVERDOSE DEATHS AND OTHER HARMS (HARM REDUCTION)

PART THREE: OTHER STRATEGIES

- I. FIRST RESPONDERS
- J. LEADERSHIP, PLANNING AND COORDINATION

CONSTITUENT RECOMMENDATIONS:

THE AGENDA ITEMS AS LISTED MAY NOT BE CONSIDERED IN SEQUENCE. PURSUANT TO 29 DEL. C. §10004(e)(2), THIS AGENDA IS SUBJECT TO CHANGE TO INCLUDE THE ADDITION OR THE DELETION OF ITEMS, INCLUDING EXECUTIVE SESSIONS, WHICH ARISE AT THE TIME OF THE MEETING